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Abstract
Background: Tertiary care hospitals are a potential source for development and spread of bacterial
resistance being in the loop to receive outpatients and referrals from community nursing homes and
hospitals. The liberal use of third-generation cephalosporins (3GCs) in these hospitals has been associated
with the emergence of extended-spectrum beta- lactamases (ESBLs) presenting concerns for bacterial
resistance in therapeutics. We studied the 3GC utilization in a tertiary care teaching hospital, in warded
patients (medical, surgical, gynaecology, orthopedic) prescribed these drugs.
Methods: Clinical data of patients (≥ 13 years) admitted to the General Hospital, Port of Spain (POSGH)
from January to June 2000, and who had received 3GCs based on the Pharmacy records were studied. The
Sanford Antibiotic Guide 2000, was used to determine appropriateness of therapy. The agency which
procures drugs for the Ministry of Health supplied the cost of drugs.
Results: The prevalence rate of use of 3GCs was 9.5 per 1000 admissions and was higher in surgical and
gynecological admissions (21/1000) compared with medical and orthopedic (8 /1000) services (p < 0.05).
Ceftriaxone was the most frequently used 3GC. Sixty-nine (36%) patients without clinical evidence of
infection received 3Gcs and prescribing was based on therapeutic recommendations in 4% of patients. At
least 62% of all prescriptions were inappropriate with significant associations for patients from gynaecology
(p < 0.003), empirical prescribing (p < 0.48), patients with undetermined infection sites (p < 0.007), and
for single drug use compared with multiple antibiotics (p < 0.001). Treatment was twice as costly when
prescribing was inappropriate
Conclusions:  There is extensive inappropriate 3GC utilization in tertiary care in Trinidad. We
recommend hospital laboratories undertake continuous surveillance of antibiotic resistance patterns so
that appropriate changes in prescribing guidelines can be developed and implemented. Though guidelines
for rational antibiotic use were developed they have not been re-visited or encouraged, suggesting urgent
antibiotic review of the hospital formulary and instituting an infection control team. Monitoring antibiotic
use with microbiology laboratory support can promote rational drug utilization, cut costs, halt
inappropriate 3GC prescribing, and delay the emergence of resistant organisms. An ongoing antibiotic
peer audit is suggested.
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Background
Appropriate use of antibiotics is central to limiting the
development and the spread of resistant bacteria in hospi-
tals and communities. Use of broad-spectrum antibiotics,
in particular the 3GCs in nosocomial infections have been
linked to the emergence of antibiotic resistance and
increase in costs [1]. The hospital setting is particularly
conducive to the development of antibiotic resistance as
patients who are severely ill, immuno-compromised or
have devices and/or implants in them are likely to receive
frequent courses of empirical or prophylactic antibiotic
therapy [2]. Furthermore, the absences of guidelines for
antibiotic use, protocols for rational therapeutics and
infection control committees have led to overuse and mis-
use of antimicrobials in different specialized units in
hospitals.
The increasing resistance to 3GCs accompanied by an
increasing cost burden has raised concerns about the
detection, prevalence, and clinical implications of infec-
tions with Escherichia coli and Klebsiella spp. An important
source of this resistance results from the production of
extended-spectrum beta-lactamases (ESBLs) by bacteria.
ESBLs are modified beta-lactamase enzymes mainly
derived from the ubiquitous TEM1/2 and SHV-1 plasmid-
mediated enzymes, which hydrolyse expanded spectrum
cephalosporins to varying degrees. Many beta-lactamases
result in resistance to 3GCs in Enterobacteriaceae. Genera
such as Enterobacter, Citrobacter and Serratia posses chro-
mosomal broad spectrum beta-lactamases which are nor-
mally repressed, and when induced result in resistance to
3GCs. Klebsiella and E. coli usually have the SHV- or Tem-
type beta-lactamases, and key mutations in these result in
true "ESBLs". ESBLs have received attention in the last dec-
ade because although penicillins, cephalosporins, or
aztreonam appear to be susceptible in vitro, ESBL produc-
ing  E. coli or  Klebsiella  spp. may demonstrate clinical
resistance to these antibiotics leading to treatment fail-
ures. Liberal use of the 3GC antibiotics has resulted in the
ESBLs conferring resistance among Enterobacter[3] and
Enterobacteriacae worldwide [4-6] compromising their
clinical use. Prior antibiotic use is an important risk factor
for colonization and bacterial infection and though gen-
erally antibiotic use cannot always be correlated with
emergent antibiotic resistance, studies have reported the
association of resistant K pneumoniae and other Enterobac-
teriaceae  and vancomycin-resistant enteroccocci with
cephalosporin use [7-11]. Recent increases in multidrug
resistant gram-negative bacilli, particularly ESBLs is of
great concern. The association between emergent ESBL-
mediated infections and 3GC use emphasizes the impor-
tance of better describing 3GC drug utilization to best
optimize their use. Few data are available in this regard
from developing countries. In the Caribbean 3GC resist-
ance amongst the Enterobacteriaceae  has been reported
from Barbados [12], and extended spectrum beta-lacta-
mase producing Enterobacteriaceae  has recently been
observed in tertiary care in Jamaica [13] and Trinidad
[14]. From unpublished reports of drug procurements for
the public sector, the third generation cephalosporins are
widely used at the General Hospital Port of Spain, which
is the largest tertiary health care institution in the country.
In order to assess the appropriateness of prescribing 3GCs
and to determine the direct cost of treatment, an audit of
prescriptions of these agents was undertaken at the
POSGH, between January to June 2000.
Methods
Setting
In Trinidad and Tobago, health care is delivered through
the public sector, though several private facilities are also
available. At the publicly-financed health care institutes
patients undergo investigations and receive treatment
without cost. There are 2 tertiary general hospitals in Trini-
dad, the General Hospitals at Port of Spain and San Fern-
ando and several secondary and primary health care
facilities where patients can access medical care. The
POSGH is the country's major health care institute and
receives referrals from all over the country including the
sister isle of Tobago. This hospital is a 900-bed institute
providing out-patient services and health care for warded
patients for over one third of Trinidad and Tobago's pop-
ulation of 1.3 million. Medical students undergoing train-
ing at the University of the West Indies, also attend
clinical rotations at this hospital.
Patients
Between January to June 2000, we conducted a cross sec-
tional study of adult in- patients (over 13 years) who had
received one or more courses of treatment with one of the
3GCs (cefotaxime, ceftriaxone, ceftazidime) available at
the POSGH. The Hospital Pharmacy identified warded
patients from the respective services based on the prescrip-
tions dispensed. Patient characteristics, clinical data and
laboratory investigations were obtained from the hospital
records. While we did consider the course of antibiotic
duration in defining appropriateness of therapy, we did
not analyse data based on use per patient days because
these data were not clearly available from the records. Spe-
cific data on the category of service, concomitant disease
and drug therapy, organ system with infection, invasive/
indwelling devices and the 3GC used were collected using
a standardized instrument.
Case definition of infection
An infection was deemed to be present when the physi-
cian's diagnosis of infection was a differential diagnosis
stated in the chart and/or in a patient who had a fever
(>100.4 C) and elevated WBC Count >12,000/cmm.BMC Infectious Diseases 2004, 4:59 http://www.biomedcentral.com/1471-2334/4/59
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On review all patients with diabetes and HIV had a clini-
cal diagnosis of infection stated in the records.
Criteria for appropriate prescription
The appropriateness of antibiotic therapy was determined
using the criteria described in the Sanford Antibiotic
Guide, 2000. Therapy was deemed to be inappropriate
based on any of the following parameters: the type of ther-
apy (prophylactic and empiric), combination of antibiot-
ics, the route of administration, the dose, and the
duration of therapy. The Sanford guide is widely accepted
in Trinidad and the Caribbean as a reference for making
appropriate therapeutic recommendations and is also
used as a reference manual by medical microbiologists.
No other guidelines are currently available in Trinidad.
The course of therapy was considered a parameter of
appropriate therapy, but a separate analysis based on this
parameter was not possible since the information was not
always available from the patient records.
Cost of antibiotic treatment
The direct cost of total antibiotic treatment was computed
using the data obtained from the National Insurance
Property Development Corporation, which is the agency
contracted by the Ministry of Health for procurement and
distribution of drugs in the public sector health institutes.
Statistical analysis
Data were analysed using EPI Info 6.4 (CDC, Atlanta GA)
and categorical variables were compared using the Odds
Ratio (95% CI) and the chi-square (X2) tests.
Results
One hundred and ninety two (192) adult patients admit-
ted to the POSGH were treated with 3GCs during the first
six months of 2000, providing a prevalence rate of use of
9.5 patients per 1000 admissions, (192/20146). The rate
of use was higher (p < 0.05) in those patients utilizing the
surgical and gynecological services (21 per 1000 admis-
sions) compared with those admitted in the medical and
orthopedic services (8 per 1000 admissions). One hun-
dred and twenty seven (66%) patients received ceftriax-
one, cefotaxime was prescribed for 51 (26.5%) patients,
and ceftazdime was administered to 14 (7.5%) patients.
The demographic characteristics of patients who received
a 3GC and factors related to infection and treatment in the
study population are shown in Table 1. Fifty eight percent
(58%) of patients were females. The mean age of patients
was 45 ± 20.56 (SD), years. The use of the third generation
cephalosporins was highest in patients utilizing the surgi-
cal facilities (44%), followed by patients in the medicine
(27.5%), gynecology (15%), and orthopedic (12.5%)
divisions. Ceftriaxone was the most widely used agent
particularly in surgical patients (61, 48%) compared with
those admitted to the medicine 24 (19%), gynecology
17(13%)and orthopedic wards 13(10%). In at least one
third of patients (63, 32.8%) factors, which could predis-
pose to infection, were identified, diabetes mellitus and
HIV/AIDS were diagnosed in 24.5% and 4.7% of patients
respectively.
There were 107(56%) patients who had fever and a high
WBC count with leucocytosis and who were considered to
have a clinically suspected infection. Thirty six percent of
patients who had no clinical evidence of infection had
received treatment with a 3GC. The most common site of
suspected infection (20.3%) was the skin and soft tissue
followed by the respiratory (10.9 %), gastrointestinal
(10.7%), and urinary (9.3%) tracts.
Table 1: Characteristics of patients treated with 3rd generation 
cephalosporins at the POSGH
Characteristics No (%)
Gender
Male 84 (42)
Female 111(58)
Age: Mean SD (Range) 45 ± 20.56(13–90 years)
Category of service
Surgery 84(43.8)
Medicine 53(27.6)
Gynaecology 29(15.1)
Orthopaedics 24(12.5)
Others (CNS, Genital, 
Septicaemia)
2
Predisposing Factors
None 129(67.2)
Diabetes Mellitus 47(24.5)
HIV/AIDS 9 (4.7)
Infection characteristics
Clinically suspected 108(56)
Clinically absent 84(44)
Site Unknown 69(35.9)
Skin and Soft tissue 39(20.3)
Respiratory tract 21(10.9)
Gastrointestinal tract 20(10.7)
Urinary tract 18(9.3)
Others 25(13.0)
Antibiotic Use
Prophylactic 57 (29.7)
Empiric 131(68.2)
Therapeutic 4(2.0)
Single drug 94(49.6)
Two or more drugs 94(49.6)
Appropriate 62(32.3)
Inappropriate 124(64.6) 6(3.1)
Undetermined
Bacteriological 
Investigations
Done 52 (27)
Not done 140 (73)BMC Infectious Diseases 2004, 4:59 http://www.biomedcentral.com/1471-2334/4/59
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Sixty eight percent (131) of patients in this study received
empirical antibiotic treatment and in 29.7% of patients
these antibiotics were prescribed as prophylactic therapy.
Only 4% of patients received 3GCs based on recom-
mended therapeutic regimens. More patients (87%) who
were admitted to the medical services received empirical
antibiotic treatment compared with patients in the surgi-
cal services (68%), (p < 0.05). Prophylactic antibiotic reg-
imens were most frequently prescribed in the orthopedic
(50%) and gynecological services (45%) in contrast to
patients in surgery (31%) who received 3GCs as prophy-
lactic therapy. However patients in the surgical units
(61%) were more likely to be administered two or more
antibiotics compared with those receiving medical care in
the orthopedic (33%) or gynecological (45%) services (p
< 0.01). Single antibiotic therapy was prevalent in the
medical, orthopedic, and gynecological services (66%,
55%, and 55% respectively). Seventy-eight percent of
those patients who did not display any clinical evidence of
infection were treated with one antibiotic. Patients with
infections of the skin and soft tissue (75%) and the uri-
nary tract (61%) were more likely to receive treatment
with two or more antibiotics compared with patients
admitted with respiratory tract infections (48%) (p <
0.05).
Biological samples were not sent to the laboratory in as
many as 73% of patients to determine a bacteriological
etiology of suspected infection. (Table 2). Of the 52
(27%) patients who were submitted to laboratory investi-
gation, a bacteriological etiology could be established in
25 (48 %) patients. The organisms which were isolated
Table 2: Microbiology investigations in patients (192) prescribed third generation cephalosporins
Type of Service No. Investigations Not done (%) Investigations Done (%) Positives (n = 52) (%)
Medicine 53 30 (55.7) 23 (44.3) 9 (39.0)
Surgery 84 69 (81.1) 15 (18.9) 10(66.6)
Gynecology 29 23 (79.3) 6 (20.7) 2 (33.3)
Orthopedics 24 16 (66.6) 8 (33.4) 3 (37.5)
Others 2 2
Total 192 140 (73) 52 (27) 25(48.0)
Table 3: Factors associated with appropriate 3rd generation cephalosporin use at the POSGH, Jan- June 2000.
Variables Appropriate Use (n = 62) Inappropriate Use (n = 124) Odds ratio (95% CI) p Value
Gender
Male 25 37
Female 53 71 0.91 (0.46–1.76) 0.88
Age (mean ± SD) 42 (18.73) 46.61(21.63) NS
Service
Gynecology 3 24 6.58 (1.69–29.89) p < 0.003
Orthopedics 6 18 2.47 (0.081–7.00)
Medicine 16 35 1.80 (0.81–4.01)
Surgery 37 45 1.00
Infection
Present 44 60 2.61 (1.30–8.28) p < 0.003
Absent 18 64
Type of infection
Site unknown 15 53 5.05 (1.45–18.10) p < 0.007
Skin and soft tissue 14 24 4.29 (0.94–20.71
Respiratory 6 13 3.13(.0.88–11.35)
Urinary tract 10 7 1.00
Therapy
Prophylactic 17 39
Empiric 45 81 1.27 (0.62–2.65) p < 0.48
Multiple therapy
Single antibiotic 18 73
2 or more antibiotics 44 51 3.50(1.73–7.11) p < 0.001BMC Infectious Diseases 2004, 4:59 http://www.biomedcentral.com/1471-2334/4/59
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were; Pseudomonas spp (7), Acinetobacter spp (3), Entero-
bacter spp (2), Klebsiella spp (2), Proteus (2) S. aureus (3),
and others (8).
An analysis of factors that were associated with the inap-
propriate use of 3GCs in the patient sample is shown in
Table 3. There was an independent association between
the type of service and inappropriate use of third genera-
tion cephalosporins and the odds of inappropriate ther-
apy with these agents was six times more for patients in
the gynecology services (odds ratio 6.58, p < 0.003) com-
pared with patients utilizing the orthopedics (odds ratio,
2.47) and medical (odds ratio 1.80)hospital services More
patients received inappropriate antibiotic treatment when
the site of infection was not determined (odds ratio 5.05)
compared with those in whom the site of infection was
located to the skin and soft tissue infection (odds ratio
3.10), and the respiratory tract (odds ratio 2.74). The
3GCs were significantly associated with inappropriate use
(odds ratio. 3.50 CI 1.73–7.11) when used as single ther-
apy than when used with multiple antibiotics.
The average duration of patient stay in the hospital was 14
± 22 days (range 1 day -150 days). Patients in the ortho-
pedic wards were hospitalized for more days (24.5 ± SD
35.28) compared with the number of days patients spent
in the medical (12.45), surgical (13.7) and gynecology (7
days) services. Interestingly, the mean duration of stay of
patients in whom antibiotic treatment was appropriate,
was not significantly different from the number of days
that patients who were treated inappropriately were
warded. The overall direct costs from use of these
antibiotics in this study was TT$ 117,432 (US$
19251.00). The cost of treatment with these antibiotics in
patients who were inappropriately treated was (TT
$79,487.00, US$ 13, 30.00) and was twice as high as the
cost of treatment for those patients who were treated
appropriately (TT$ 35, 138.00, US$ 5767)
Discussion
The extensive use of third generation cephalosporin anti-
biotics has caused the emergence of extended spectrum
beta-lactamases in Gram-negative bacteria worldwide [3-
6]. More third generation cephalosporins are being widely
used in hospitals for empirical and prophylactic therapy,
and as their use extends across the board, more organisms
will develop resistance to them presenting the threat of
antimicrobial ineffectiveness in life threatening infec-
tions. Several investigators have developed and evaluated
cost effective programs and adherence to hospital antibi-
otic guidelines to control antibiotic abuse [15-17]. The
active promotion of guidelines increased appropriate pre-
scribing of 3GCs from 21–52% over three years [18].
Though an Infection Control Committee at the POSGH
had developed an antibiotic policy earlier for rational use
of antimicrobial agents, the Committee did not formally
approve the guidelines, they were not disseminated to all
physicians and several were unaware of their formulation.
A systematic review and evaluation of the guidelines was
never conducted despite increasing antimicrobial resist-
ance to third generation cephalosporins in this hospital
[14]. It was therefore believed to be timely to undertake a
pharmacy audit of use and cost of third generation cepha-
losporins in this teaching hospital.
In our study, the prevalence rate of use of 3GCs was lower
than the reported rate of 43 per 1000 admissions for
ceftriaxone in 51 Victorian Hospitals in Australia of which
82% was prescribed as empirical treatment [19]. Our data
reveals extensive overall inappropriate use of these drugs
(62%) at the POSGH in Trinidad, with a rate that is higher
than an earlier literature report (31%) [20]. Inappropriate
use of the cephalosporins was seven times more common
in the gynecological services compared with other services
(odds ratio 6.58 P < 0.003) in this hospital which pro-
vides clinical clerkship teaching for graduating medical
students from the University of the West Indies. Inappro-
priate antibiotic use has been reported from teaching hos-
pitals in Aberdeen with significant empirical overuse [21]
in New York [22] in the surgical practice [74%], in China
[23] where inappropriate 3GC use was an independent
risk factor for significant high mortality, in Malaysia [24]
for patients in the medical wards (22–65%), in South
Africa [25] for patients in the gynaecology ward (54%),
and in Thailand (91%) for all departments [26]. There
were twice as many patients who received inappropriate
prophylactic or empirical therapy with the 3GCs com-
pared with those who received appropriate treatment. We
found higher inappropriate use of cefotaxime and ceftri-
axone when these agents were used as single agents rather
than in combination therapy with other antimicrobial
agents. We believe this practice may have followed from
the convenience of a single daily dose by intramuscular
injection particularly for ceftriaxone, which was the most
frequently used 3GC.
Third generation cephalosporins were introduced in the
Caribbean between the late eighties and the early nineties
and soon after in 1993, the first isolation of resistant
Gram-negative bacilli resistant to them was demonstrated
in Barbados [12]. In Jamaica, K. pneumoniae isolates con-
firmed to be ESBL producers have recently been reported
in the University Hospital of the West Indies [13]. The
3GCs were introduced to the POSGH formulary in 1990
and their use increased by 48% and 22% from 1995
to1998 and 1998 to 2001 respectively. Cefotaxime was
then, the most widely used member of the class and the
only member to be available in the public sector health
institutes. Resistance to cefotaxime and ceftriaxone in
Trinidad, has been demonstrated for isolates of entero-BMC Infectious Diseases 2004, 4:59 http://www.biomedcentral.com/1471-2334/4/59
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bacter (35%,15%), proteus (28%, 8%), acinetobacter
(75%, 61%), providencia (75%, 50%) and klebsiella
(6%,5%) for all specimens between January to June 2001
at the Port of Spain General Hospital (unpublished data),
but blood culture isolates such as klebsiella (25%) and
pseudomonas (90%) were resistant to cefotaxime and/or
ceftriaxone. The resistance rate of Enterobacter spp to cefo-
taxime and ceftriaxone was 53% and 37% respectively in
the Intensive Care Unit at this hospital. It is interesting
that only 4% of prescriptions were based on therapeutic
regimen following culture and sensitivity results in our
study, and in 73% of patients with suspected infection
bacteriological confirmatory tests were never done and
3GCs were prescribed. We believe high inappropriate use
of these antibiotics has contributed to increasing multiple
antibiotic resistance and extended spectrum beta-lacta-
mase producing enterobacteriaceae observed in this hos-
pital [14].
The cost of inappropriate antibiotic use was twice as much
for patients who were treated appropriately and highlights
irrational antibiotic consumption at the hospital, prompt-
ing protocols for rational antibiotic prescribing and utili-
zation review. The World Health Organization has
recommended multifaceted strategies to improve hospi-
tal-prescribing practices such as the development of
consensus guidelines, educational activities and rapid
feedback to prescribers about inappropriate use to reduce
overuse of antibiotics in the hospital [27]. Restriction of
cephalosporin use has demonstrated significant cost sav-
ings and improved antibiotic susceptibility with reduced
infection-related hospital mortality in critically ill patients
[28]. Restructuring the formulary to rationalize antimicro-
bial use with restricted use of third generation cepha-
losporins would impact positively in curtailing antibiotic
resistance and decrease selective pressure from the overuse
of these agents. Moreover the spiraling costs of unwanted
antibiotic therapy will be limited with resultant benefits
for the consumer and the health care provider in the pub-
lic health sector. The study highlights the need for an anti-
biotic audit and invites an ongoing peer audit.
Conclusions
This first audit on 3GC use from the Caribbean demon-
strates inappropriate use of these drugs in tertiary care and
presents opportunities to develop consensus guidelines
for rational use of these drugs in hospitals. We recom-
mend microbiological services in the hospitals undertake
continuous surveillance of resistance patterns, to guide in
the development of prescribing guidelines. Such guide-
lines should be widely disseminated and implemented in
these institutions, so that prescribers remain informed of
rational therapeutics. This study highlights the need to
constitute an antibiotic monitoring team comprising a
pharmacist, physician, medical microbiologist and infec-
tion control nurse to periodically review and evaluate the
use and cost of antibiotics at the major tertiary care hospi-
tal in Trinidad, to assist clinicians in optimizing clinical
care of patients with Gram-negative infections.
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